Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.008
Buy
RSI(14)
51.830
Neutral
STOCH(KDJ)(9,3,3)
48.348
Neutral
ATR(14)
0.047
High Vlolatility
CCI(14)
21.675
Neutral
Williams %R
55.080
Sell
TRIX(12,20)
0.313
Sell
StochRSI(14)
0.000
Sell
Search
Vistagen Therapeutics Inc
VTGNAdd to Watchlist
0.625USD
-0.026-3.95%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
24.76MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Vistagen Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Vistagen Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 186 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 3.73.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vistagen Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Vistagen Therapeutics Inc Highlights
StrengthsRisks
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
Growing
The company is in a growing phase, with the latest annual income totaling USD 486.00K.
Fairly Valued
The company’s latest PE is -0.33, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 15.04M shares, decreasing 44.07% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 160.79K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.77.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
3.725
Target Price
+472.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Vistagen Therapeutics Inc is 6.55, ranking 229 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 303.00K, representing a year-over-year increase of 29.49%, while its net profit experienced a year-over-year increase of 34.14%.
Score
Financials
9.16
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.68
Operational Efficiency
2.72
Growth Potential
6.07
Shareholder Returns
7.11
Vistagen Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Vistagen Therapeutics Inc is 6.93, ranking 189 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.33, which is -98.00% below the recent high of -0.01 and -1209.98% above the recent low of -4.33.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 186/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Vistagen Therapeutics Inc is 6.00, ranking 333 out of 382 in the Biotechnology & Medical Research industry. The average price target is 13.50, with a high of 19.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
3.725
Target Price
+472.55%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Vistagen Therapeutics Inc
VTGN
5
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Vistagen Therapeutics Inc is 4.79, ranking 335 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.70 and the support level at 0.55, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.645
Sell
MA10
0.626
Sell
MA20
0.612
Buy
MA50
0.603
Buy
MA100
0.612
Buy
MA200
2.128
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Vistagen Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 37.96%, representing a quarter-over-quarter decrease of 34.37%. The largest institutional shareholder is James Simons, holding a total of 291.30K shares, representing 0.74% of shares outstanding, with 755.88% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Vistagen Therapeutics Inc is 1.25, ranking 321 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.31. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.31
VaR
+7.78%
240-Day Maximum Drawdown
+89.69%
240-Day Volatility
+186.29%
Return
Best Daily Return
60 days
+14.85%
120 days
+14.85%
5 years
+676.65%
Worst Daily Return
60 days
-7.72%
120 days
-80.25%
5 years
-85.99%
Sharpe Ratio
60 days
+1.52
120 days
-1.47
5 years
+0.23
Risk Assessment
Maximum Drawdown
240 days
+89.69%
3 years
+96.13%
5 years
+99.47%
Return-to-Drawdown Ratio
240 days
-0.83
3 years
-0.24
5 years
-0.20
Skewness
240 days
-5.81
3 years
+24.92
5 years
+29.46
Volatility
Realised Volatility
240 days
+186.29%
5 years
+189.30%
Standardised True Range
240 days
+30.01%
5 years
+165.24%
Downside Risk-Adjusted Return
120 days
-129.59%
240 days
-129.59%
Maximum Daily Upside Volatility
60 days
+52.62%
Maximum Daily Downside Volatility
60 days
+44.46%
Liquidity
Average Turnover Rate
60 days
+2.64%
120 days
+6.21%
5 years
--
Turnover Deviation
20 days
+79.03%
60 days
+15.50%
120 days
+171.90%
Peer Comparison
Biotechnology & Medical Research
Vistagen Therapeutics Inc
VTGN
5.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
